Almost every page on this site deals with TUDCA as a liver compound or a neuroprotective one. Mood is the obvious gap, and it is not an arbitrary one: the case for looking at depression runs through the same endoplasmic reticulum stress pathway that the rest of the site is built on, and separately through bile acid signalling between the gut and the brain.
The honest summary is that three rodent studies report an antidepressant-like effect, that a growing set of human studies find bile acid abnormalities in people with major depressive disorder without giving anyone TUDCA, and that these two bodies of evidence are further apart than they look. Nothing here is medical advice, and depression is a condition with treatments that have human outcome data behind them.
Key Takeaways
- Endoplasmic reticulum stress is an established line of research in depression, with a review literature arguing that persistent ER stress in the hippocampus, amygdala and striatum contributes to the disorder[1].
- In rats exposed to chronic unpredictable mild stress, TUDCA produced antidepressant and anxiolytic behaviour, lowered IL-1 beta and NLRP3 in the hippocampus and medial prefrontal cortex, and restored dopamine and norepinephrine. It did not change serotonin levels[2].
- In female mice given corticosterone, TUDCA increased sucrose preference and locomotor activity, reduced immobility time, lessened hippocampal CA3 neuronal damage and activated the BDNF/TrkB/CREB pathway[3].
- In hyperglycaemic mice with depression-like behaviour, TUDCA relieved both the molecular and the behavioural changes, supporting ER stress as a downstream consequence of calcium dysregulation[4].
- Human studies consistently find altered bile acid profiles in major depressive disorder, in cohorts of 60, 164 and 181 people[5][6][7]. None of them gave anyone TUDCA.
- There is no clinical trial of TUDCA for depression. The largest trial where humans took TUDCA for any neurological indication found it safe at 2 g/day but found no clinical benefit[8].
The Mechanistic Case, Stated Carefully
The endoplasmic reticulum folds, modifies and transports proteins, and neurons do a great deal of that work. When ER homeostasis is disturbed, the unfolded protein response tries to restore folding capacity, and when the disturbance is excessive or persistent, cells die. A review literature argues that when this happens in the hippocampus, amygdala and striatum, it contributes to the development of depression, and it catalogues antidepressant drugs that act on the pathway[1].
That is the first half of the argument and it is about a pathway, not a compound. The second half is that TUDCA is one of the better-characterised suppressors of that pathway, which is why it appears in Parkinson models and retinal work. Neither half establishes that a bile acid taken by mouth changes mood in a person.
The Three Rodent Studies
A 2026 study used chronic unpredictable mild stress in male rats and measured what TUDCA did to monoamines. Behaviourally, TUDCA showed antidepressant and anxiolytic properties. Biochemically, it markedly reduced the stress-driven rise in IL-1 beta and NLRP3 in both the hippocampus and the medial prefrontal cortex[2].
The neurotransmitter result is more specific than the usual summary suggests. TUDCA failed to alter serotonin in either region. It restored the reduced dopamine and norepinephrine in the hippocampus and improved the dopamine imbalance in the prefrontal cortex, increased tyrosine hydroxylase expression in the hippocampus, and reduced the elevated monoamine oxidase A protein in both areas[2]. If the effect is real, it is a catecholamine story rather than a serotonin one, which is worth noting given that the most commonly prescribed antidepressants work on serotonin reuptake.
A 2025 study took a different model and a different population: female mice given corticosterone, chosen because depression disproportionately affects women. TUDCA raised sucrose preference and locomotor activity and cut immobility time, three standard behavioural readouts. Nissl staining showed reduced neuronal damage in the hippocampal CA3 region, and western blotting pointed to activation of the BDNF/TrkB/CREB pathway alongside changes in glucocorticoid receptor-related proteins[3].
The third is indirect but mechanistically the tightest. Researchers studying hyperglycaemia showed that streptozotocin-treated mice developed depression-like behaviour alongside raised hippocampal CHOP, neuronal loss and reduced SERCA2. Infusing a SERCA2 inhibitor into the hippocampus produced ER stress and depression-like behaviour on its own. Treating with TUDCA relieved both the molecular and the behavioural changes, which is what placed ER stress downstream of the calcium problem rather than beside it[4].
The Human Data, and What It Is Not
People with major depressive disorder do appear to have different bile acids in their blood. A 2022 study of 31 patients with first-episode major depressive disorder and 29 healthy controls found taurolithocholic acid, glycolithocholic acid and lithocholic acid 3-sulfate significantly lower in patients, and several of those species correlated negatively with Hamilton Depression scores[5].
A 2026 study of 90 patients and 74 controls measured nine bile acids and found 3-beta-cholic acid and 3-beta-deoxycholic acid significantly lower in patients, with a calculated oxidative stress index raised. The cholic acid measure correlated negatively with the cognitive disturbance score, and there was no association with anxiety symptoms[6].
The largest looked at 104 patients and 77 controls with serum metabolomics plus faecal metagenomic sequencing in a subset, and validated in a second cohort of 40 and 40. It reported abnormal bile acid metabolism in patients that related to cognitive dysfunction, and identified gut bacteria that tracked with the bile acid changes[7]. A 2025 review pulls this together as a bile acid-mediated gut-brain axis, noting both receptor-dependent and receptor-independent mechanisms and behavioural abnormalities in receptor knockout animals[9].
Now the part that matters. Every one of those studies measured molecules in blood or stool. None administered TUDCA, and none can say whether the bile acid differences are a cause of depression, a consequence of it, or a marker of something else that travels with it, such as diet, appetite change, body weight or medication. A metabolite that separates two groups is a biomarker candidate, not a treatment.
What Happened When Humans Actually Took TUDCA
TUDCA has been given to humans in a randomised, double-blind, placebo-controlled trial, just not for depression. In progressive multiple sclerosis, 47 participants received 2 g/day or placebo for 16 weeks. The primary outcomes were safety and tolerability, and those were met: adverse events did not differ between arms and serum bile acids rose in the treated group. On the exploratory clinical and fluid biomarker outcomes there were no significant differences[8].
That trial is the most useful human anchor available for a mood question, precisely because it is not about mood. It establishes that a real human dose is tolerable over months. It also demonstrates the ordinary outcome of taking a promising preclinical compound into people, which is that the behavioural and clinical endpoints do not move. The side effect profile and dosing page cover what that dose looks like in practice.
What This Evidence Can and Cannot Support
It supports the statement that TUDCA produces antidepressant-like behaviour in three separate rodent models with three different induction methods, and that plausible mechanisms have been identified in each: catecholamines and neuroinflammation in one, BDNF signalling in another, ER calcium handling in the third.
It does not support any claim about human mood. There is no trial, no open-label series and no dose-finding work in depression. The human bile acid studies are observational and cross-sectional. Depression is a serious condition, effective treatments exist, and anyone who is struggling should be talking to a clinician rather than evaluating a supplement against a set of mouse behavioural tests.
Frequently Asked Questions
Can TUDCA treat depression?
Unknown, and untested in humans. Three rodent studies report antidepressant-like effects through different mechanisms[2][3][4]. No clinical trial of TUDCA for depression has been published.
Does TUDCA raise serotonin?
Not in the study that measured it. In chronically stressed rats, TUDCA failed to alter serotonin in the hippocampus or the prefrontal cortex, while restoring dopamine and norepinephrine and reducing monoamine oxidase A[2]. If there is an effect, the animal data point at catecholamines rather than serotonin.
Why do people with depression have different bile acids?
Nobody knows yet. Multiple cohorts confirm the difference exists[5][6][7], and a review frames it as gut-brain axis signalling[9], but cross-sectional data cannot separate cause from consequence. Diet, weight change and medication all affect bile acids and all travel with depression.
Is TUDCA safe to take alongside an antidepressant?
No interaction study exists for that combination. TUDCA has documented interaction considerations of its own, and the honest answer is that this is a question for the prescriber who knows the rest of the regimen, not a question a supplement page can answer.
References
- Role of endoplasmic reticulum stress in depression (Review). Mol Med Rep (2019).
- Tauroursodeoxycholic acid alleviates depression-like behavior induced by chronic unpredictable mild stress through amelioration of catecholamine imbalance. Brain Res (2026).
- Tauroursodeoxycholic acid mitigates depression-like behavior and hippocampal neuronal damage in a corticosterone model of female mice. Naunyn Schmiedebergs Arch Pharmacol (2025).
- Pharmacological activation of SERCA2 reverses ER calcium dysregulation and depression-like behaviors in hyperglycemic mice. Sci Rep (2025).
- Abnormal gut microbiota and bile acids in patients with first-episode major depressive disorder and correlation analysis. Psychiatry Clin Neurosci (2022).
- Altered serum 3beta-hydroxy bile acids in major depressive disorder and associations with symptom dimensions. J Affect Disord (2026).
- Gut microbiota dysbiosis promotes cognitive impairment via bile acid metabolism in major depressive disorder. Transl Psychiatry (2024).
- Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease. Med (2025).
- Evidence and Mechanism of Bile Acid-Mediated Gut-Brain Axis in Anxiety and Depression. Am J Pathol (2025).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
